Abstract

IDEXX Laboratories will report second-quarter 2026 results on August 04, 2026 Pre-Market; this preview summarizes consensus forecasts, last quarter performance, key segment dynamics, and institutional sentiment into a concise framework.

Market Forecast

Based on the company’s indicated projections for the current period, revenue is forecast at 1.20 billion US dollars, up 12.49% year over year, with EBIT estimated at 408.84 million US dollars (+15.86% YoY) and EPS of 3.95 (+19.53% YoY). While a company-level gross margin outlook was not explicitly provided, the last reported gross margin level offers context; the market expects steady profitability with net income leverage implied by the EPS growth rate. The main business is anticipated to benefit from resilient recurring diagnostic demand and installed base utilization, with a stable mix supporting margins. The most promising segment appears to be the Companion Animal Group, which generated 1.05 billion US dollars last quarter and continues to anchor revenue growth given test menu utilization and premium analyzer penetration.

Last Quarter Review

IDEXX Laboratories posted revenue of 1.14 billion US dollars, a gross profit margin of 63.35%, net profit attributable to shareholders of 278.00 million US dollars, and a net profit margin of 24.41%; adjusted EPS was 3.47, rising 17.23% year over year. The quarter delivered solid top-line expansion with operating leverage, demonstrated by the positive EPS surprise against expectations. Main business highlights: Companion Animal Group contributed 1.05 billion US dollars, Water delivered 50.27 million US dollars, Livestock, Poultry and Dairy recorded 32.48 million US dollars, and Other reached 4.02 million US dollars, with Companion Animal Group remaining the core growth driver.

Current Quarter Outlook

Main business: Companion Animal Group

Companion Animal Group remains the central earnings engine this quarter, supported by recurring testing volumes, growth in reference lab throughput, and continued adoption of high-throughput in-practice analyzers. Volume utilization and a favorable product mix in consumables typically support stable to higher contribution margins, which should align with the expected EPS acceleration relative to revenue. Commercial execution in key regions combined with pricing discipline in annual contracts will be important to hold gross margin near the recent run-rate. Watch for any commentary on analyzer placements and upgrade cycles, as these tend to foreshadow multi-quarter consumables pull-through and can shift the revenue growth trajectory for the segment.

Most promising business: Companion Animal Group growth vectors

Within Companion Animal Group, growth vectors this quarter likely include higher premium test usage, broader menu adoption, and digital diagnostics integration, which together support mid-teens profit growth. The forecast setup implies improved operating efficiency and potentially modest mix benefits as higher-value tests scale across the installed base. Given last quarter’s 1.05 billion US dollars in revenue from the segment, even incremental utilization gains can add meaningful absolute dollars, magnifying EBIT growth above revenue growth. Monitoring regional contributions and clinic workflow adoption can help gauge the durability of the momentum through the back half of the year.

Stock-price drivers: Margin durability and demand visibility

The stock is likely to react to the balance of growth and profitability indicators—specifically any commentary on gross margin trajectory relative to the recent 63.35% level and the net margin cadence against the 24.41% baseline. Investors will parse guidance color around consumables utilization, analyzer placements, and reference lab volumes, which directly frame revenue visibility into the next two quarters. Upside risk may come from better-than-expected EPS flow-through if operating expense growth remains controlled, while downside risk would be tied to signs of slower clinic traffic or a softer upgrade cycle affecting analyzer placements and future consumables pull-through.

Analyst Opinions

Across recent institutional commentary, the majority view skews bullish, emphasizing resilient pet healthcare spending and recurring diagnostic demand that should sustain double-digit revenue growth and positive operating leverage. Well-followed analysts highlight the constructive setup into the print, pointing to EPS growth outpacing revenue growth as evidence of margin discipline and scaling benefits from the installed base. The bullish case anticipates continued momentum in core diagnostics, with particular attention to multi-quarter consumables pull-through from new and upgraded analyzers, and sees the current quarter’s revenue and EPS forecasts as achievable with room for moderate upside if utilization trends hold.